HIV 臨床試驗市場 - 全球產業規模、佔有率、趨勢、機會和預測，按階段、按研究設計、按贊助商、按地區和競爭進行細分，2020-2030 年預測

2024 年全球愛滋病毒臨床試驗市值為 15.8 億美元，預計到 2030 年將達到 22 億美元，預測期內複合年成長率為 5.62%。全球愛滋病毒臨床試驗市場涵蓋廣泛的研究計畫和投資，旨在開發創新的愛滋病毒治療、療法和預防解決方案。製藥公司、研究機構和醫療保健組織透過進行臨床前和臨床試驗來評估新藥和治療方案的安全性、有效性和長期影響，在推動這個市場方面發揮著至關重要的作用。這些試驗對改善患者治療效果、降低傳播率和提高愛滋病毒感染者的生活品質做出了重大貢獻。

該市場的關鍵方面之一是抗逆轉錄病毒療法 (ART) 的不斷發展，它有助於控制病毒並防止其發展為愛滋病。臨床試驗對於測試下一代 ART、長效注射劑和新型治療策略（包括基於免疫的療法和基因編輯技術）至關重要。此外，人們正在廣泛研究愛滋病毒疫苗、暴露前預防（PrEP）和單株抗體等預防措施，以抑制新的感染。政府機構、非營利組織和私營部門實體不斷增加的投資推動了市場的發展，這些投資資助了旨在找到有效治療方法或徹底消除病毒的研究計畫。臨床試驗設計的進步，例如分散試驗和自適應方法，也提高了效率和患者參與度。儘管存在監管複雜性和道德考量等挑戰，全球愛滋病毒臨床試驗市場仍然是愛滋病毒研究的基石，為全球對抗這一持續的健康挑戰做出了貢獻。

主要市場促進因素

愛滋病毒/愛滋病疫情持續存在

主要市場挑戰

恥辱與歧視

主要市場趨勢

長效抗愛滋病毒療法 (ART)

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球 HIV 臨床試驗市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依階段分類（第一階段、第二階段、第三階段、第四階段）
  • 依研究設計分類（介入性研究、觀察性研究、擴大准入研究）
  • 按贊助商分類（製藥和生物製藥公司、非營利組織、其他）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第 6 章：北美 HIV 臨床試驗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 7 章：歐洲 HIV 臨床試驗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太地區 HIV 臨床試驗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 韓國
  • 日本
  • 澳洲

第 9 章：南美 HIV 臨床試驗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲愛滋病毒臨床試驗市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Syneos Health Inc
• PPD Inc
• IQVIA Inc
• PAREXEL International Corp
• ICON PLC
• WuXi AppTec Co Ltd
• Janssen Global Services LLC
• Gilead Sciences Inc
• GSK PLC
• Charles River Laboratories Inc

第 15 章：策略建議

第16章 關於出版商,免責事項

Global HIV Clinical Trials Market was valued at USD 1.58 Billion in 2024 and is expected to reach USD 2.20 Billion by 2030 with a CAGR of 5.62% during the forecast period. The Global HIV Clinical Trials Market encompasses a wide range of research initiatives and investments aimed at developing innovative treatments, therapies, and preventive solutions for HIV. Pharmaceutical companies, research institutions, and healthcare organizations play a crucial role in driving this market by conducting preclinical and clinical trials to assess the safety, efficacy, and long-term impact of new drugs and treatment regimens. These trials contribute significantly to improving patient outcomes, reducing transmission rates, and enhancing the quality of life for individuals living with HIV.

One of the key aspects of this market is the continuous evolution of antiretroviral therapies (ART), which help manage the virus and prevent its progression to AIDS. Clinical trials are essential for testing next-generation ARTs, long-acting injectables, and novel therapeutic strategies, including immune-based therapies and gene editing techniques. Additionally, preventive measures such as HIV vaccines, pre-exposure prophylaxis (PrEP), and monoclonal antibodies are being extensively studied to curb new infections. The market is driven by rising investments from government agencies, nonprofit organizations, and private sector entities that fund research initiatives aimed at finding a functional cure or complete eradication of the virus. Advances in clinical trial designs, such as decentralized trials and adaptive methodologies, are also enhancing efficiency and patient participation. Despite challenges such as regulatory complexities and ethical considerations, the Global HIV Clinical Trials Market remains a cornerstone of HIV research, contributing to the global fight against this persistent health challenge.

Key Market Drivers

Persistence of the HIV/AIDS Epidemic

The HIV/AIDS epidemic has been a global health crisis for decades, affecting millions of people worldwide. According to the IAVI report, an estimated 39.9 million people were living with HIV/AIDS in 2023, with 1.3 million new HIV cases recorded during the year. While significant progress has been made in understanding and managing the virus, the persistence of HIV/AIDS continues to drive research and development efforts. According to the National AIDS Control Organization (NACO) HIV estimates for 2023, India's overall HIV epidemic remains low, with an adult prevalence rate of 0.20%. However, certain states continue to report significantly higher prevalence rates, including Mizoram (2.73%) and Nagaland (1.37%), followed closely by Manipur (0.87%). Additionally, Andhra Pradesh (0.62%), Telangana (0.44%), Meghalaya (0.43%), Karnataka (0.42%), and Punjab (0.42%) recorded adult prevalence rates exceeding 0.40%. Mizoram and Nagaland have the highest number of districts with a prevalence rate above 1%. Among the 96 districts with prevalence rates ranging from 0.40% to 1%, 75 are located in Andhra Pradesh, Karnataka, Manipur, Meghalaya, Punjab, and Telangana. While adult HIV prevalence has shown a declining trend across most states and union territories over the years, the increasing prevalence in Punjab and certain northeastern states (excluding Nagaland and Manipur) remains a concern. This persistence not only underscores the ongoing need for effective treatments and preventive measures but also plays a pivotal role in boosting the growth of the Global HIV Clinical Trials Market. The persistence of the HIV/AIDS epidemic creates a continuous demand for innovative solutions. Despite the availability of antiretroviral therapy (ART), new challenges such as drug resistance, long-term side effects, and accessibility issues persist. These challenges drive researchers and pharmaceutical companies to seek better treatments, including new drug formulations, combination therapies, and alternative treatment strategies.

As HIV continues to evolve, drug-resistant strains of the virus have emerged. This poses a significant threat to individuals living with HIV and underscores the need for clinical trials to develop new drugs and treatment regimens that can effectively combat drug-resistant variants. The persistence of HIV/AIDS means that diverse patient populations with varying demographics, medical histories, and viral strains are still affected.for instance, Despite a low prevalence rate, India continues to bear a substantial HIV burden, with an estimated 2.544 million people living with HIV (PLHIV) in 2023.

Clinical trials need to include a wide range of participants to ensure that new treatments and preventive measures are effective across different groups. This diversity is essential for achieving a comprehensive understanding of HIV and tailoring therapies to specific needs.

HIV affects diverse populations across the globe. Increased funding supports the expansion of clinical trials into regions with high HIV prevalence, including low- and middle-income countries. This geographical diversity is crucial for ensuring that research findings are applicable to a broad range of individuals. Funding enables researchers to implement effective recruitment and retention strategies for clinical trial participants. Financial incentives, community engagement programs, and support services for trial participants become more feasible, resulting in better enrollment and participation rates. With increased funding, clinical trials can become more patient-centric. This means taking into account the needs and preferences of trial participants, including diverse demographics, cultural backgrounds, and medical histories. Patient-centric trials are more likely to yield relevant and practical results. Additional funding allows for the exploration of promising drug candidates and preventive measures that might otherwise go untested due to budget constraints. Researchers can take risks on unconventional approaches, potentially uncovering groundbreaking solutions.

Public awareness campaigns inform individuals about the importance of HIV clinical trials and how they can participate. When more people are aware of these trials, they are more likely to consider participating, thereby expanding the pool of potential participants. This inclusivity ensures that clinical trial results are more representative of diverse populations.

Key Market Challenges

Stigma and Discrimination

Stigma and discrimination surrounding HIV continue to pose significant challenges in the field of clinical trials. Many individuals fear that participating in a trial will expose their HIV status, leading to social isolation, workplace discrimination, or even loss of employment and housing. This fear is particularly pronounced in regions where HIV-related stigma is deeply entrenched in societal and cultural norms. As a result, many eligible candidates hesitate to enroll in clinical studies, limiting the diversity of participants and potentially skewing research outcomes. Additionally, stigma can discourage open conversations about trial participation between healthcare providers and patients, further reducing enrollment rates. Addressing these concerns requires strong advocacy, confidentiality measures, and public awareness campaigns to reduce misconceptions about HIV.

Key Market Trends

Long-Acting Antiretroviral Therapies (ART)

Long-acting antiretroviral therapies (ART) represent a transformative advancement in HIV treatment, addressing key challenges related to adherence and treatment efficacy. Traditional ART requires daily oral administration, which can be burdensome for patients, leading to missed doses and the potential for viral resistance. Long-acting formulations, such as injectables and implants, offer a solution by significantly reducing dosing frequency. By administering ART every few weeks or months, these formulations enhance treatment adherence and minimize the stigma associated with daily pill intake.

Current clinical trials are evaluating the safety, efficacy, and pharmacokinetics of various long-acting ART formulations. For instance, cabotegravir and rilpivirine, a combination of long-acting injectable ART, have demonstrated promising results in maintaining viral suppression with monthly or bimonthly dosing. Additionally, pharmaceutical companies are developing subcutaneous implants capable of delivering ART over extended periods, further improving patient convenience. Beyond treatment adherence, long-acting ART may have significant public health benefits, particularly for populations facing social and economic barriers to consistent healthcare access. People living in remote areas, those with unstable housing, or individuals with mental health challenges may benefit immensely from reduced dosing schedules. However, challenges such as potential drug resistance, injection site reactions, and manufacturing scalability remain critical areas of ongoing research.

The development of long-acting ART aligns with global efforts to control the HIV epidemic by improving treatment outcomes and reducing transmission rates. As more long-acting formulations advance through late-stage trials, their potential integration into routine HIV care could redefine treatment strategies, making HIV management more effective and accessible on a global scale.

Key Market Players

• PPD Inc
• IQVIA Inc
• PAREXEL International Corp
• ICON PLC
• Syneos Health Inc
• WuXi AppTec Co Ltd
• Janssen Global Services LLC
• Gilead Sciences Inc
• GSK PLC
• Charles River Laboratories Inc

Report Scope:

In this report, the Global HIV Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV Clinical Trials Market, By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

HIV Clinical Trials Market, By Study Design:

• Interventional Studies
• Observational Studies
• Expanded Access Studies

HIV Clinical Trials Market, By Sponsor:

• Pharmaceutical & Biopharmaceutical Companies
• Non-Profit Organizations
• Others

HIV Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HIV Clinical Trials Market.

Available Customizations:

Global HIV Clinical Trials market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global HIV Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.2. By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies)
  • 5.2.3. By Sponsor (Pharmaceutical & Biopharmaceutical Companies, Non-Profit Organizations, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America HIV Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Study Design
  • 6.2.3. By Sponsor
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States HIV Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Study Design
      • 6.3.1.2.3. By Sponsor
  • 6.3.2. Mexico HIV Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Study Design
      • 6.3.2.2.3. By Sponsor
  • 6.3.3. Canada HIV Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Study Design
      • 6.3.3.2.3. By Sponsor

7. Europe HIV Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Study Design
  • 7.2.3. By Sponsor
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France HIV Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Study Design
      • 7.3.1.2.3. By Sponsor
  • 7.3.2. Germany HIV Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Study Design
      • 7.3.2.2.3. By Sponsor
  • 7.3.3. United Kingdom HIV Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Study Design
      • 7.3.3.2.3. By Sponsor
  • 7.3.4. Italy HIV Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Study Design
      • 7.3.4.2.3. By Sponsor
  • 7.3.5. Spain HIV Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Study Design
      • 7.3.5.2.3. By Sponsor

8. Asia-Pacific HIV Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Study Design
  • 8.2.3. By Sponsor
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China HIV Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Study Design
      • 8.3.1.2.3. By Sponsor
  • 8.3.2. India HIV Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Study Design
      • 8.3.2.2.3. By Sponsor
  • 8.3.3. South Korea HIV Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Study Design
      • 8.3.3.2.3. By Sponsor
  • 8.3.4. Japan HIV Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Phase
      • 8.3.4.2.2. By Study Design
      • 8.3.4.2.3. By Sponsor
  • 8.3.5. Australia HIV Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Phase
      • 8.3.5.2.2. By Study Design
      • 8.3.5.2.3. By Sponsor

9. South America HIV Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Study Design
  • 9.2.3. By Sponsor
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil HIV Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Study Design
      • 9.3.1.2.3. By Sponsor
  • 9.3.2. Argentina HIV Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Study Design
      • 9.3.2.2.3. By Sponsor
  • 9.3.3. Colombia HIV Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Study Design
      • 9.3.3.2.3. By Sponsor

10. Middle East and Africa HIV Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Study Design
  • 10.2.3. By Sponsor
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa HIV Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Study Design
      • 10.3.1.2.3. By Sponsor
  • 10.3.2. Saudi Arabia HIV Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Study Design
      • 10.3.2.2.3. By Sponsor
  • 10.3.3. UAE HIV Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Study Design
      • 10.3.3.2.3. By Sponsor

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Syneos Health Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. PPD Inc
• 14.3. IQVIA Inc
• 14.4. PAREXEL International Corp
• 14.5. ICON PLC
• 14.6. WuXi AppTec Co Ltd
• 14.7. Janssen Global Services LLC
• 14.8. Gilead Sciences Inc
• 14.9. GSK PLC
• 14.10. Charles River Laboratories Inc

15. Strategic Recommendations

16. About Us & Disclaimer